| November 1 |
Orexigen Therapeutics to Present Data Supporting Novel, PreClinical
Drug Combination for Schizophrenia |
| November 1 |
Nebivolol Lowers Blood Pressure in African Americans With Stage
I-II Hypertension as Demonstrated in a Study Published in the
Journal of Clinical Hypertension |
| November 1 |
Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for
Once Daily Dosing in Preclinical Studies |
| November 1 |
BioGeneriX and Neose to Host Conference Call to Present
GlycoPEG-GCSF Phase I Data |
| November 1 |
Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial
Results for Lead Product Candidate AM103 and Initiates Clinical
Studies for the 2nd Entry Molecule for the Treatment of Respiratory
and Cardiovascular Disease |
| November 1 |
Argos Therapeutics Presents Positive Data on its Personalized
Cancer Immunotherapy Programs at ISTBC Meeting |
| November 1 |
Procrit (Epoetin Alfa) Data to Be Presented at American Society of
Nephrology Annual Meeting |
| November 1 |
Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial
Hypertension to Be Announced Before Market Open on Thursday,
November 1, 2007 |
| November 1 |
Incyte Reviews Positive Proof-of-Concept Clinical Results Achieved
During the Third Quarter; Cites Continued Progress in Multiple Drug
Development Programs; Announces Third Quarter Financial Results |
| November 1 |
Proteon Therapeutics to Present at Annual Meeting of American
Society of Nephrology in San Francisco on November 2, 2007 |
| November 1 |
BioDelivery Sciences International Reveals Additional Details
Regarding BEMA LA |
| November 1 |
UPDATE: Nebivolol Lowers Blood Pressure in African Americans With
Stage I-II Hypertension as Demonstrated in a Study Published in the
Journal of Clinical Hypertension |
| November 1 |
Abbott Researchers Target Neuronal Nicotinic Receptors for
Treatment of Pain and Cognition |
| November 1 |
Trial Shows Minocycline Has a Harmful Effect on Patients with Motor
Neuron Disease |
| November 1 |
New Data Presented at UEGW Confirm Effectiveness and Safety of
Resolor for Patients with Chronic Constipation |
| November 1 |
Mayo Clinic Study Shows Drug Could Effectively Treat, Prevent the
Spread of Breast Cancer |
| November 1 |
Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets
Primary Endpoint |
| November 1 |
Obesity Common in Children with Heart Disease |
| November 1 |
Endo announces update on Phase III-program for Orexo's pain product
Rapinyl |
| November 1 |
GlobeImmune Announces Presentation of Additional Phase 1b Hepatitis
C Results at American Association for the Study of Liver Diseases
2007 Annual Meeting |
| November 1 |
Hythiam's Prometa Treatment Program Demonstrates Statistically
Significant Reduction in Methamphetamine Cravings in Randomized,
Double-Blind Placebo-Controlled Study |
| November 1 |
Protox Announces Positive Final Data from Prostate Cancer Study |
| November 1 |
Common Medications Provide Equal Blood Pressure Control |
| November 2 |
ThromboGenics and BioInvent Announce Publication of Exciting Data
on a Novel Class of Angiogenesis Inhibitors in Cell |
| November 2 |
Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM
3454 in Alzheimer's Disease |
| November 2 |
Phase II Study Shows that Nitazoxanide Significantly Improves
Response to Standard of Care in Patients with Chronic Hepatitis C |
| November 2 |
Data from Completed Phase 1 Studies of Novel Adenosine A2b
Antagonist CVT-6883 Show Safety, Tolerability and Potential Utility
in Chronic Pulmonary and Inflammatory Diseases |
| November 2 |
First Studies Demonstrating Greater than Sixty Percent Sustained
Viral Response Rates with Half the Standard Treatment Duration in
Genotype 1 Chronic Hepatitis C Patients |
| November 2 |
IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data
Confirms Statistically Superior Overall Survival in Osteosarcoma
Patients |
| November 2 |
Treatment with Pegasys/Copegus Provides Hope for Hepatitis C
Patients Whose Infection Did Not Initially Respond to
Peg-Intron/Ribavirin |
| November 2 |
Roche's Investigational Polymerase Inhibitor, Combined with Pegasys
and Copegus, Shows Potent Antiviral Activity in Treatment of
Chronic Hepatitis C at Four Weeks |
| November 2 |
Gilead Announces 48-Week Data from Two Pivotal Phase III Studies
Evaluating Viread For the Treatment of Chronic Hepatitis B |
| November 2 |
ACADIA Pharmaceuticals to Present Preclinical Data on Its Advanced
Schizophrenia Programs at the 37th Annual Meeting of the Society
for Neuroscience |
| November 2 |
Progen to Present Additional Analysis of Data from PI-88 Phase 2
Liver Cancer Study at American Association for the Study of Liver
Diseases |
| November 2 |
Pharmasset Presents R7128 14-Day Monotherapy Study Results for the
Treatment of Chronic Hepatitis C |
| November 2 |
IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE)
Compassionate Use Program |
| November 2 |
IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show
Treatment Well Tolerated With Positive Survival Trend in Lung
Cancer Patients |
| November 2 |
IDM Pharma Announces Updated Phase 2 UVIDEM Results Showing Durable
Disease Control and Tolerability in Advanced Melanoma Patients |
| November 2 |
New clinical results support telomerase vaccination in breast
cancer |
| November 2 |
Ninety-one Percent of Baraclude (entecavir) Treated Patients in a
Four-Year Cohort Demonstrated Virologic Suppression to Undetectable
Levels |
| November 2 |
St. Jude Finds Anti-Leukemia Drug Increases Patient Fatigue |
| November 2 |
Flutiform - Results of Safety Study |
| November 2 |
Arpida Presents Data on Iclaprim at Scientific Congress in Germany |
| November 2 |
BioInvent and ThromboGenics Announce Publication of Exciting Data
on a Novel Class of Angiogenesis Inhibitors in Cell |
| November 2 |
Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine
Trial |
| November 2 |
First Studies Demonstrating Greater than Sixty Percent Sustained
Viral Response Rates with Half the Standard Treatment Duration in
Genotype 1 Chronic Hepatitis C Patients |
| November 5 |
ZIOPHARM Presents Positive Phase II Data for ZIO-201 in Soft Tissue
and Bone Sarcomas at Connective Tissue Oncology Society (CTOS)
Annual Meeting |
| November 5 |
Sangamo BioSciences Presents Postive Data Showing Pain Reduction by
Novel ZFP Therapeutic at Society for Neuroscience Meeting |
| November 5 |
Osteologix Announces Positive Phase II Study of Its Investigational
Osteoporosis Drug, NB S101; Trial Meets Primary Endpoint |
| November 5 |
Human Genome Sciences Announces Full Presentation of
Quality-of-Life Results From Phase 2b Trial of Albuferon for
Hepatitis C |
| November 5 |
Human Genome Sciences Announces Presentation at AASLD of Results of
Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C |
| November 5 |
Positive Results From Peregrine Pharmaceuticals' Bavituximab Phase
l HCV Trial Presented at AASLD Meeting |
| November 5 |
Nventa Presents HspE7 Data at International HPV Conference |
| November 5 |
Medivation's MDV3100 Demonstrates Substantial PSA Reductions in
First Patient Groups Treated in Phase 1-2 Hormone Refractory
Prostate Cancer Trial |
| November 5 |
New Data Examines the Effect of Adding a Statin to Optimized
Treatment for Patients with Advanced Heart Failure |
| November 5 |
Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007
American Society of Nephrology Conference |
| November 5 |
Gilead Announces Phase I Data for GS 9190, An Investigational
Compound for the Treatment of Chronic Hepatitis C |
| November 5 |
MannKind Announces Positive Results from a Phase 1a Study of a
GLP-1 Formulation |
| November 5 |
Affymax Announces Hematide Successfully Restores Hemoglobin in
Patients with Pure Red Cell Aplasia (PRCA) |
| November 5 |
Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III
Study Against Clopidogrel |
| November 5 |
New Data Presented on Gardasil, Merck's Cervical Cancer Vaccine, in
Women Through Age 45 |
| November 5 |
Abbott's Investigational Simcor Offers Comparable LDL Lowering to
Simvastatin and Significantly Raises HDL and Lowers Triglycerides
in Phase III Study |
| November 5 |
Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase
2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma |
| November 5 |
Treatment with PEGASYS/COPEGUS Provides Hope for Hepatitis C
Patients Whose Infection Did Not Initially Respond to
Peg-Intron/Ribavirin |
| November 5 |
Positive Results from CVBT's Phase I No-Option Heart Disease
Clinical Trial Will Be Presented at the American Heart
Association's Annual Meeting |
| November 5 |
Synvista Collaboration Demonstrates in Preclinical Studies the
Mechanism for Defective Cholesterol Transport in Patients with
Diabetes |
| November 5 |
New Data Examines The Effect Of Adding A Statin To Optimised
Treatment For Patients With Advanced Heart Failure |
| November 5 |
Suven Life Sciences Presenting Pre-clinical Data of their NCEs at
Society for Neuroscience Annual Meeting, SFN-2007 at San Diego, USA |
| November 5 |
Reported to the American Heart Association Scientific Sessions:
Newly Discovered Heart Wall Abnormality May Predict Risk of Stroke
Associated with Patent Foramen Ovale, AGH Cardiologists Report |
| November 5 |
New Lipitor Data Analyses from Landmark Ideal and SPARCL Trials to
Be Presented at Upcoming Annual Scientific Sessions of the American
Heart Association |
| November 5 |
At TCT 2007, Cappella Demonstrates Procedural Advantages and
Clinical Benefits of Its Technology in Treating Coronary
Bifurcations |
| November 5 |
Ranexa Significantly Reduces Incidence of CV Death, MI or Recurrent
Ischemia in MERLIN TIMI-36 Patients With Elevated BNP |
| November 5 |
Metabasis Presents Preclinical Results at AASLD Showing MB07811,
Its Novel Product Candidate for the Treatment of Hyperlipidemia,
Reduces Liver Fat |
| November 5 |
Seattle Genetics Reports Positive Phase I Data with SGN-35 in
Hodgkin Lymphoma |
| November 5 |
Progen Presents Additional Analysis of Data from PI-88 Phase 2
Liver Cancer Study at American Association for the Study of Liver
Diseases |
| November 5 |
Advanced Cell Technology and the Casey Eye Institute at Oregon
Health & Science University Present Results of Functional
Studies for RPE Program at Neuroscience 2007 |
| November 5 |
New Study Provides Scientific Evidence That DermaLastyl Face Cream
Reduces Wrinkles |
| November 5 |
Cleveland Clinic Study Suggests Failure of HDL-Raising Drug
Torcetrapib is Likely Compound Specific |
| November 5 |
Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in
Multiple Preclinical Studies of Liver Disease |
| November 5 |
Reverse Cholesterol Transport by RVX-208 a Small Molecule for
ApoA-I Production Increase Presented at American Heart Association
Scientific Meeting |
| November 5 |
Pooled Analysis of Long-Term Data Suggests Cypher Sirolimus-Eluting
Coronary Stent Provides Sustained Clinical Benefits in Patients
with Coronary Artery Disease Compared to Bare Metal Stents |
| November 5 |
Preschoolers with Three or More Coexisting Disorders Show No
Response to ADHD Medication Treatment |
| November 5 |
Pipex Pharmaceuticals' Anti-Copper Coprexa Demonstrates 40%
Reduction of Insoluble Amyloid Beta in Animal Models of Alzheimer's
Disease |
| November 5 |
SPP100 (tekturna/rasilez) Decreases Proteinuria in Diabetic
Patients |
| November 5 |
Avigen's AV411 Shows Promising Initial Results for Neuropathic Pain
Phase IIa Data Presented At the International Conference On the
Mechanisms and Treatment of Neuropathic Pain |
| November 5 |
Avigen Presents At the 37th Annual Meeting of the Society for
Neuroscience Presentation of AV650 Phase I Data Shows No Evidence
of Sedation |
| November 5 |
CorMedix Studies Show That Removing 'Toxic' Iron Could Slow
Progression of Chronic Kidney Disease |
| November 6 |
Merck's Investigational Extended-Release Niacin/Laropiprant
(CORDAPTIVE(TM)) Coadministered with Simvastatin Had Significant
Additive Effects on LDL-C, HDL-C and Triglycerides in Phase III
Study |
| November 6 |
Shire Announces Results of Fosrenol Study in Pre-Dialysis CKD Stage
3 & 4 Patients |
| November 6 |
BioLineRx Presents BL-1040 Data at the American Heart Association
Scientific Sessions 2007 |
| November 6 |
MacroChem Announces Positive Interim Phase 2 Data for EcoNail in
the Treatment of Onychomycosis |
| November 6 |
Poniard Pharmaceuticals Announces Positive Preliminary
Bioavailability Data From Ongoing Phase 1 Trial of Oral Picoplatin
in Patients With Solid Tumors |
| November 6 |
German and U.S. Researchers Show TB4's Cardioprotective Effects in
Ischemia-Reperfusion Injury |
| November 6 |
Addition of Integrilin (Eptifibatide) to Bivalirudin Plus Standard
of Care Inhibits Platelet Aggregation in Patients Undergoing
Elective Coronary Stenting |
| November 6 |
Synvista Announces New Data Showing Haptoglobin Type Predicts
Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes
in Patients with Diabetes |
| November 6 |
Neurogen Announces Adipiplon Preclinical and Clinical Data to Be
Presented at Neuroscience 2007 |
| November 6 |
Results from Phase 1 Study of AVEO's Novel Triple VEGF Receptor
Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved
Partial Response or Stable Disease |
| November 6 |
A Life Sciences Renaissance: 100th Peer-Reviewed Publication
Enabled by 454 Sequencing |
| November 6 |
Sanofi Pasteur Presents Positive Results of Tetravalent Dengue
Candidate Vaccine |
| November 6 |
Neurogen Announces Aplindore Preclinical Data to Be Presented at
Neuroscience 2007 |
| November 6 |
AVI BioPharma to Present on NEUGENE Countermeasures to Biological
Threats at U.S. Department of Defense 2007 Biodefense Research
Conference |
| November 6 |
Can-Fite: CF101 May Be Effective for the Treatment of Crohn's
Disease |
| November 6 |
Data Presented at the American Heart Association Scientific
Sessions 2007 Demonstrated Increased HDL with Actos (pioglitazone
HCl) Slowed the Progression of Carotid Intima-Media Thickness in
Patients with Type 2 Diabetes |
| November 6 |
VIA Pharmaceuticals Presents Data at American Heart Association
Meeting Showing VIA-2291 Significantly Reduces Inflammation in
Preclinical Model of Atherosclerosis |
| November 6 |
Photo: Scientists Complete Genome Sequence of Fungus Responsible
for Dandruff, Skin Disorders |
| November 6 |
Ranexa Significantly Reduces Ischemia in Women in MERLIN TIMI-36
Study |
| November 6 |
This Book Meets The Long Awaited Need For A Comprehensive Overview
Of The Biological Role Of High Density Lipoproteins |
| November 6 |
Acusphere Announces Data Demonstrating Imagify Perfusion Stress
Echo is Well-tolerated and as Effective as Nuclear Perfusion
Imaging for Evaluating Chest Pain Patients at Risk for Heart Attack |
| November 6 |
World Think Tank on Type 1 Diabetes Meets in Miami |
| November 6 |
Lipitor Provides Greater Benefit Compared to Simvastatin in
Patients with a History of Heart Attacks Who Have Had Subsequent
Cardiovascular Events |
| November 6 |
New Study Reveals MRSA Bacteria Common Among Pigs and Farm Workers |
| November 6 |
Presentation of Phase IIa Results for Cytos Biotechnology's
Hypertension Vaccine at the American Heart Association Scientific
Sessions 2007 |
| November 6 |
Micromet's BiTE Antibodies Reveal Unique Mode of Action |
| November 6 |
Sangamo BioSciences Announces Presentation of Phase 1b ZFP
Therapeutic Data at Society for Neuroscience Meeting |
| November 6 |
Millennium Announces MLN1202 Significantly Reduced Marker of
Systemic Inflammation and Identifies Genomic Biomarker For
Responders |
| November 6 |
Encysive Pharmaceuticals Announces Presentation of Sitaxsentan Data
in Eisenmenger Syndrome At AHA Meeting |
| November 7 |
LifeCycle Pharma Announces Positive Results From Head-to-Head
Clinical Trial of LCP-Tacro Versus Advagraf For the Prevention of
Organ Rejection After Transplantation |
| November 7 |
BioGeneriX and Neose Technologies Announce Positive Data from Two
Phase I Studies of GlycoPEG-GCSF |
| November 7 |
NicOx' Naproxcinod ABPM Data Presented at American Heart
Association |
| November 7 |
ARCA Discovery Announces Data Demonstrating Potential for
Bucindolol as Targeted Therapy in Heart Failure, Atrial
Fibrillation, and Ventricular Arrhythmia |
| November 7 |
Data Show Geron's Cell-Based Therapeutic for Spinal Cord Injury
Survives and Exhibits Remyelination for at Least Nine Months
Following Injection |
| November 7 |
New Clinical Study Shows Limbrel as Effective as Naproxen for Knee
Osteoarthritis |
| November 7 |
AlphaRx's Vansolin On Track To Enter Human Trials in '08 |
| November 7 |
OctoPlus Presents Positive Phase IIa Study Results for Locteron in
Hepatitis C at AASLD Conference |
| November 7 |
New Findings Provide Insight into Treatment of Hypertension in
Mexican Americans |
| November 7 |
A Phase II, Randomized, Double Blind, Placebo-Controlled
Dose-Escalating Study, Meets the Clinical Endpoints of MTR106
Tablets During the Treatment of Acute Migraine Attacks Without Aura
in Females |
| November 7 |
Raven to Present Updated Phase 1 Clinical Study Results of RAV12
Therapeutic Antibody for Treatment of Adenocarcinomas |
| November 7 |
Study Shows Tekturna, the First and Only Approved Direct Renin
Inhibitor, Reduces a Key Marker of Heart Failure Severity |
| November 7 |
BRIGHT Results Show Less Pain and Higher Patient Satisfaction with
Betaseron than with Rebif |
| November 7 |
Presentation of Phase IIa Results for Cytos Biotechnology’s
Hypertension Vaccine at the American Heart Association Scientific
Sessions 2007 |
| November 7 |
Medication Does Not Appear to Improve Symptoms or Outcomes for
Patients with Acute Heart Failure |
| November 7 |
COURAGE Sub-study: PCI Outperforms Drugs-Only |
| November 7 |
Fresenius Medical Care Announces: Continued Positive Data from
CARE-2 Database |
| November 7 |
SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown
to Inhibit Platelet Aggregation in PCI Patients |
| November 7 |
Study Shows Vernakalant Hydrochloride is Effective in Conversion to
Normal Heart Rhythm in Atrial Fibrillation Patients Following
Cardiac Surgery |
| November 7 |
New Clinical Data Show Solvay’s Fenofibrate Cuts Risk of Main
Causes of Vision Loss in Patients with Type 2 Diabetes |
| November 7 |
GlobeImmune Announces Presentation of Results from a Randomized
Phase 1b Study of the GI-5005 Tarmogen in Patients with Chronic
Hepatitis C Infection |
| November 7 |
Cost-Effectiveness Study Supports Use of EUFLEXXA by
Rheumatologists for Pain Relief in Patients with Knee
Osteoarthritis |
| November 7 |
Nabi Biopharmaceuticals Announces Successful Completion of NicVAX
Phase 2b Trial; Drug Shows Statistically Significant Rates of
Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12
Months |
| November 7 |
New Data Illustrates Variances in the Use of Evidence-Based Heart
Failure Treatments |
| November 7 |
New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's
Crestor (Rosuvastatin Calcium) on Atherosclerosis in Patients With
Two or More Risk Factors for Cardiovascular Disease |
| November 7 |
Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant
Clinical Benefit in Patients With Peripheral Arterial Disease |
| November 7 |
Retrospective Analysis Finds That Initiation of Insulin Glargine in
Patients With Type 2 Diabetes was Associated With a Lower Incidence
Rate of Myocardial Infarction as Compared With NPH Insulin |
| November 7 |
CHW Researcher Presents Results of ACT-Sponsored Trial
Demonstrating Efficacy of ACT Myoblast Therapy for Heart Failure at
AHA Meeting |
| November 7 |
Data from STEP Study Presented at Open Scientific Session Confirm
Merck's Investigational HIV Vaccine was not Effective |
| November 7 |
Advanced Cell Technology Announces 12-Month Results of Myoblast
Therapy Trial |
| November 7 |
Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve
Regeneration Program at Society for Neuroscience Meeting |
| November 7 |
Statement of Anthony S. Fauci, M.D., Director National Institute of
Allergy and Infectious Diseases On the Release of New Data from the
HVTN 502 (STEP) HIV Vaccine Study |
| November 7 |
Scientists Compare Twelve Fruit Fly Genomes |
| November 7 |
Leukemia Drug Proves Safe and Effective Over the Long Term |
| November 8 |
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved
Arthritis, Skin and Nail Manifestations in Patients with Psoriatic
Arthritis |
| November 8 |
Genasense Triple Combination Therapy in Advanced Melanoma Presented
at Chemotherapy Foundation Symposium |
| November 8 |
Milnacipran Demonstrated Significant Improvement in Pain and the
Core Symptoms of Fibromyalgia Syndrome, Data Show |
| November 8 |
VistaGen CEO to Present Overview of Recent Stem Cell-Based Drug
Discovery and Development Advances at Society of Biomolecular
Sciences Symposium |
| November 8 |
CV Therapeutics' Selective Adenosine A1 Agonist Tecadenoson Shows
Synergistic Effect with Ultra Low Dose Beta Blocker in Preclinical
Atrial Fibrillation Model |
| November 8 |
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved
Arthritis, Skin and Nail Manifestations in Patients with Psoriatic
Arthritis |
| November 8 |
Two Pivotal Phase III Studies for Roche's Actemra (tocilizumab)
Demonstrate Significant Improvement in Rheumatoid Arthritis
Symptoms |
| November 8 |
Immunosyn Corporation Releases SF-1019 Study Results |
| November 8 |
LifeCycle Pharma Announces Positive Results From Head-to-Head
Clinical Trial of LCP-Tacro Versus Advagraf For the Prevention of
Organ Rejection After Transplantation |
| November 8 |
Medarex Announces Presentations on UltiMAb Antibodies at 71st
Annual Meeting of the American College of Rheumatology |
| November 8 |
Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417
for Symptoms of Bipolar Disorder |
| November 8 |
Abbott Research Demonstrates Viability of Combining Antibody
Functions to Target Two or More Disease-Causing Processes |
| November 8 |
MedImmune Presents Data from Its Advancing Inflammatory Disease
Portfolio at 71st Annual Meeting of The American College of
Rheumatology |
| November 8 |
Lodotra Shows a Sustained Reduction of Morning Stiffness in
Patients with Rheumatoid Arthritis Treated with Lodotra for 12
Months |
| November 8 |
New Actemra Data Shows Significant Benefit for Patients Suffering
From Rheumatoid Arthritis |
| November 8 |
Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in
Ankylosing Spondylitis Patients Treated with Humira (adalimumab) |
| November 8 |
Cimzia (certolizumab pegol), Significantly Reduces Structural
Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One
Year |
| November 8 |
Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic
Eye |
| November 8 |
Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417
for Symptoms of Bipolar Depression |
| November 8 |
Genasense Triple Combination Therapy in Advanced Melanoma Presented
at Chemotherapy Foundation Symposium |
| November 8 |
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of
Ankylosing Spondylitis According to Phase 3 Study Findings |
| November 8 |
New Data Show That Half of Patients with Active Early Rheumatoid
Arthritis Achieved Clinical Remission at One Year When Treated with
Enbrel (etanercept) Plus Methotrexate |
| November 8 |
MediQuest Announces Positive Results from Phase III Study |
| November 9 |
Biogen Idec's Baminercept, the First Lymphotoxin-(beta) Pathway
Inhibitor in Development, Shows Promise in Patients with Rheumatoid
Arthritis |
| November 9 |
Trubion Pharmaceuticals Announces Presentation of Positive Data
From Phase IIb and Re-treatment Studies With TRU-015 in Patients
With Rheumatoid Arthritis |
| November 9 |
Cougar Biotechnology Presents Positive CB7630 Phase II Data at
Chemotherapy Foundation Symposium |
| November 9 |
Five-Year Data Demonstrate Long-Term Efficacy and Safety with
Orencia (abatacept) in Adults with Rheumatoid Arthritis Who had an
Inadequate Response to Methotrexate |
| November 9 |
Human Genome Sciences Reports Positive Data from Long-Term
Treatment with LymphoStat-B in Patients with Active Systemic Lupus
Erythematosus |
| November 9 |
Inspire Announces Oral Presentation of Phase 2 Epinastine Nasal
Spray Data at American College of Allergy, Asthma & Immunology
Meeting |
| November 9 |
Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with
Advanced Renal Cell Carcinoma Presented Today at the 25th Annual
Chemotherapy Foundation Symposium |
| November 9 |
Pharmexa A/S (DK) - Promising clinical results from new HIV vaccine |
| November 9 |
Sirtris Scientific Advisory Board Member Describes a Novel
Endogenous SIRT1 Activator |
| November 9 |
Biogen Idec's Baminercept, the First lymphotoxin-b PATHWAY
Inhibitor in development, Shows Promise in Patients with Rheumatoid
Arthritis |
| November 9 |
New Phase III Trial Results for Rivaroxaban to be Presented at the
49th Annual Meeting of the American Society of Hematology |
| November 9 |
Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic
Purpura (ITP) Patients in Phase 2 Study |
| November 9 |
Alexion Pharmaceuticals to Present Data on Soliris (Eculizumab) and
PNH at the 2007 American Society of Hematology (ASH) Annual Meeting |
| November 9 |
Genmab to Present Zanolimumab and Ofatumumab Data at ASH |
| November 9 |
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard
of Care in Second Line Treatment of Small Cell Lung Cancer |
| November 12 |
Hollis-Eden Pharmaceuticals Presents Data on Apoptone and Potential
Role of Adrenal Steroid Hormones for the Treatment of Cancer |
| November 12 |
ImmuneRegen BioSciences' Viprovex Demonstrates Further Evidence for
Effectiveness Against Influenza Virus, Including Avian Flu |
| November 12 |
NanoViricides Drug Effectiveness Confirmed Against Rabies and
Influenzas |
| November 12 |
Nuvelo Announces Presentations on Alfimeprase, rNAPc2, and the
Leukemia TherapeuticS Program at the American Society of Hematology
49th Annual Meeting |
| November 12 |
Development of Dyax's Patient Reported Outcome for the Treatment of
Hereditary Angioedema Presented at ACAAI Meeting |
| November 12 |
Lev Presents Significant Data from Pivotal Phase III Trial of
Cinryze in Acute Treatment of Hereditary Angioedema at ACAAI
Meeting |
| November 12 |
New Data Presented at ACAAI Informs on the Safety and Efficacy of
Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old
with Year-Round Allergic Rhinitis |
| November 12 |
New Data Shows Veramyst Effectively Treats Symptoms of Perennial
Allergic Rhinitis |
| November 12 |
VistaGen Publishes Preclinical Data Supporting the Therapeutic
Potential of AV-101 for Parkinson's Disease |
| November 12 |
L-Proline Stabilizer Used in the Intravenous Immunoglobulin Product
Privigen Shows No Neurological Side Effects Compared with Currently
Used Stabilizers |
| November 12 |
Dynavax Presents New Analysis of Tolamba Data at ACAAI Meeting |
| November 12 |
New Hope in Immunodeficiency Treatment for Improved Tolerability
and Convenience in the use of Immune Globulin Intravenous (Human)
10% Liquid (Privigen) |
| November 12 |
Major Phase 3 Trial Shows Zevalin Extends Progression-free Survival
in One of the Most Common Types of Lymphoma |
| November 12 |
Akela Pharma Announces Final Positive Results from its Growth
Hormone Releasing Hormone (GHRH) Phase II Trial |
| November 12 |
Celsion Corporation Announces Liver Phase I Abstract Accepted for
Oral Presentation at 8th World Congress of IHPBA |
| November 12 |
VGX Pharmaceuticals' SynCon Pandemic Flu Vaccine Protects Against A
Lethal Challenge of Live Virus in Pre-Clinical Animal Models |
| November 12 |
Eliminating Influence of Hyperactive Genes That Help Regulate Cell
Development Shows Potential as Additional Target Therapy for
Chronic Myelogenous Leukemia |
| November 12 |
Post-Hoc Data Show Daily Activity Participation, Independence and
Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid
Arthritis After Treatment with Orencia (Abatacept) |
| November 12 |
ISTA Pharmaceuticals Presents Results from Two Phase III Clinical
Trials of Xibrom QD (Once-daily) Formulation at the American
Academy of Ophthalmology Annual Meeting |
| November 12 |
NicOx’ Naproxcinod Phase 3 Results Presented at American
College of Rheumatology |
| November 12 |
Media Advisory - New Study Shows Reduction in Anti-Depressant
Withdrawal Symptoms |
| November 13 |
Journal of Neuroimmunology Publishes Study Results Showing That
Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord
Injury Evades Direct Attack by the Human Immune System |
| November 13 |
Isis Reports New Data for Mipomersen in Routine High Cholesterol
Patients and Provides Cumulative Safety Summary |
| November 13 |
New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody
Being Developed by Peregrine is as Effective as Avastin in
Preclinical Cancer Models |
| November 13 |
NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at
AAO |
| November 13 |
Preclinical Data Published in Cancer Science Show AVEO's Novel Oral
EGFR Inhibitor AV-412 Effective in Drug-Resistant Cancers |
| November 13 |
Tumor Eradication Article Published by Cancer Research |
| November 13 |
Diabetes Rates Are Increasing Among Youth |
| November 14 |
Study Shows Organon's Asenapine Demonstrates Efficacy and
Tolerability in Treating Acute Schizophrenia |
| November 14 |
Nymox Reports Completion of Large New 2 Year Follow-up Study of
NX-1207 for BPH |
| November 14 |
Scientists Zero in on the Cellular Machinery that Enables Neurons
to Fire |
| November 14 |
M. D. Anderson Researchers Identify Tumor- Suppressor Gene for Lung
Cancer |
| November 15 |
Introgen Therapeutics Highlights Summary Advexin Data at the Third
International Workshop on Mutant p53 and the Symposium on
Li-Fraumeni Syndrome |
| November 15 |
Pramlintide and Leptin Combination Treatment Demonstrates 12.7
Percent Weight Loss in 24-Week Clinical Obesity Study |
| November 15 |
Cethromycin Achieves All Endpoints in Second Pivotal Phase III
Trial for Treatment of Pneumonia |
| November 15 |
Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug
for Bone Diseases |
| November 15 |
The New England Journal of Medicine Publishes First Clinical
Results for MedImmune's Chitinase-like Protein YKL-40 in Patients
With Asthma |
| November 15 |
Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug
for Bone Diseases Safety Analysis Shows Good Tolerance with No
Serious Adverse Reactions |
| November 15 |
New England Journal of Medicine Study Shows Erbitux Improves
Survival in Advanced Colorectal Cancer |
| November 15 |
Forteo Increased Spine Bone Mineral Density in Patients with
Glucocorticoid-Induced Osteoporosis |
| November 15 |
New Data for Menveo Vaccine Show Excellent Immune Response and
Broad Protection for Infants Against Meningococcal Meningitis |
| November 15 |
New Anemia Measure Predicts Risk of Death in Dialysis Patients |
| November 15 |
Oramed Pharmaceuticals Successfully Completes Animal Studies for
Phase 1B Clinical Trials Of Its Oral Insulin Capsule |
| November 15 |
NCI Researchers Uncover Unusual Association Between Cell Survival
Proteins and Ovarian Cancer Aggressiveness |
| November 15 |
Grantees of the Avon Foundation Breast Cancer Prevention Research
Initiative Gather in Houston to Report Interim Findings |
| November 16 |
ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling
Clinical Study |
| November 16 |
Thallion Announces Positive Safety and Efficacy Data From ECO-4601
Phase I/II Trial |
| November 16 |
Genmab to Present HuMax-IL8 Pre-Clinical Data |
| November 16 |
Study Shows Weight-Loss Drug Rimonabant is Associated with Severe
Adverse Psychiatric Events |
| November 19 |
Hollis-Eden Pharmaceuticals Presents Data Demonstrating Triolex
Provides Benefit in Additional Animal Model of Rheumatoid Arthritis |
| November 19 |
Avastin Shows Encouraging Results in Phase II Study in Patients
With the Most Aggressive Form of Brain Cancer |
| November 19 |
Affitech-Identified Fully Human Anti-VEGF Antibody Candidate is as
Effective as Avastin in Preclinical Cancer Models |
| November 19 |
Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic
Antibody for Treatment of Adenocarcinomas |
| November 19 |
Avastin Shows Encouraging Results in Phase II Study in Patients
With the Most Aggressive Form of Brain Cancer |
| November 19 |
Data on Avicena's Drug Candidate HD-02 Presented at the 2007 World
Congress on Huntington's Disease |
| November 19 |
Pharmexa Provides Update on the HeptoVax Trial of GV1001 In Liver
Cancer |
| November 19 |
TransMolecular Reports Positive Phase 2 Data from Study of
(131)Iodine Radiolabeled TM-601 in Recurrent Glioma |
| November 19 |
Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the
Treatment of Recurrent Malignant Gliomas Presented at the 12th
Annual Scientific Meeting of Society for Neuro-Oncology |
| November 19 |
The Aethlon Hemopurifier Reverses Immune Suppression in Cancer |
| November 19 |
Solagran Limited's Bioeffectives to be Used to Treat Alzheimer's
Patients and Alcoholics in Russia |
| November 20 |
Cytos Biotechnology presents encouraging phase IIa study results
for its melanoma vaccine CYT004-MelQbG10 |
| November 20 |
Combining Medications Often Best Strategy to Battle Rheumatoid
Arthritis |
| November 20 |
New Phase 2 Study Shows That Liraglutide Leads to Significant
Weight Loss in Obese People |
| November 21 |
Brostallicin Trial Data Demonstrates Encouraging Anti-tumor
Activity in Patients With Chemotherapy-Resistant Cancers |
| November 21 |
Neose Announces Data Presentations on GlycoPEGylated Factor VIIa at
the American Society of Hematology Annual Meeting |
| November 21 |
Positive Outcome of Drug-Drug Interaction Trial With Intravenous
Iclaprim |
| November 21 |
Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical
Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data |
| November 26 |
Isotechnika Inc. completes critical study |
| November 26 |
CuraGen and TopoTarget Announce Presentations on Belinostat at the
Upcoming American Society of Hematology 49th Annual Meeting |
| November 26 |
Drug Combination Effective Against Multiple Myeloma, Researchers
Show |
| November 26 |
Nereus Pharmaceuticals to Present Research at the Annual Meeting of
the American Society of Hematology |
| November 26 |
New Data to Support Velcade (Bortezomib) For Injection Based
Therapies as Setting New Standards in The Care of Newly Diagnosed
Patients With Multiple Myeloma |
| November 26 |
Oral Drug Sets a New Survival Standard for Bone Marrow Cancer |
| November 26 |
ImmunoGen, Inc. Announces Presentations on Clinical-Stage Compounds
at ASH Annual Meeting |
| November 26 |
CytRx Reports Favorable Safety and Tolerability Results from High
Dose, 28-Day Clinical Trial with Arimoclomol |
| November 26 |
Novelos Therapeutics to Webcast Investor and Analyst Day on Nov
27th in NYC |
| November 26 |
Cardiome Updates Guidance |
| November 26 |
Two Major Phase III Studies Report Oral Revlimid (Lenalidomide)
Plus Dexamethasone Shows Increased Overall Survival Advantage to
Dexamethasone Plus Placebo in Previously Treated Multiple Myeloma
Patients in The New England Journal of Medicine |
| November 26 |
NovaBay Announces Positive Phase I Study Results with Its Lead
Aganocide Compound |
| November 26 |
AVANT's Partner, GlaxoSmithKline, Announces New Data Published in
The Lancet Show That Rotarix Provides Sustained and Broad
Protection During the First Two Years of Life |
| November 26 |
Kiadis Pharma Presents ATIR and Rhitol Data at ASH and NIH
Presentation on ATIR at ASH |
| November 26 |
New Data Published in The Lancet Show GSK's Rotarix Offers
Protection Against the Most Common Circulating Rotavirus Types |
| November 26 |
Moffitt Cancer Center Takes Part in Newly Published Study in This
Week's New England Journal of Medicine |
| November 26 |
Updated Revlimid (Lenalidomide) Plus Dexamethasone Data in
Previously Treated Multiple Myeloma Reported in The New England
Journal of Medicine |
| November 26 |
The International Myeloma Foundation Says Revlimid Extends Survival
with Positive Implications for a Wide Range of Blood Cancers |
| November 26 |
NCI Researchers Identify Novel Mechanism for Spread of Sarcoma
Tumors |
| November 26 |
SIGA Chief Scientific Officer, Dr. Dennis Hruby, to Present ST-246
Progress and Human Clinical Safety Study Data to The World Health
Organization (WHO) |
| November 26 |
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH
for Treatment of Hereditary Angioedema |
| November 26 |
VasoGenix Pharmaceuticals Presents Data Related to CGRP (Calcitonin
Gene Related Peptide) for Heart Failure Patients |
| November 27 |
Osiris Therapeutics Announces Positive One Year Data from
Chondrogen Trial for Knee Repair |
| November 27 |
Dynavax Reports Progress in Lupus Program With Inhibitor of TLR7
and TLR9 |
| November 27 |
Treating Depression Prolongs Life for Older People with Diabetes |
| November 27 |
Study Shows Cholera Can be Controlled With Oral Vaccines |
| November 27 |
Cell Therapeutics, Inc. Plans to Submit sBLA for Zevalin
Consolidation of First Remission in Advanced Stage Follicular
Lymphoma in 2008 |
| November 27 |
Eurand Completes Bioavailability Study of Zentase |
| November 27 |
San Diego Company Formed Around Breakthrough in Stem Cell
Reprogramming in Primates |
| November 27 |
VioQuest Pharmaceuticals Announces Presentation on VQD-002 at the
Upcoming American Society of Hematology 49th Annual Meeting |
| November 27 |
EPIX Pharmaceuticals to Present at CBI's Alzheimer's Drug
Development Summit |
| November 27 |
Gemin X Announces Publication of Unique Mechanism of Action of
Obatoclax in Proceedings of the National Academy of Sciences |
| November 27 |
Depression Linked to Bone-Thinning in Premenopausal Women |
| November 27 |
BrainStorm Cell Therapeutics' Adult Stem Cell Approach More
Relevant Than Embryonic Stem Cell Therapies |
| November 27 |
Abbott to Present Comprehensive Safety and Efficacy Data on XIENCE
V Drug Eluting Stent to FDA Advisory Committee on Nov. 29 |
| November 27 |
Amicus Therapeutics to Host R&D Day |
| November 28 |
Transport's Phase 2 Data Show Single Treatment SoloVir ETS
Significantly Stops Progression of Cold Sore Episode |
| November 28 |
Preclinical Data on ARIAD's Multi-Targeted Kinase Inhibitor to Be
Presented at ASH Annual Meeting |
| November 28 |
Antares Pharma and Population Council Announce Phase I Results |
| November 28 |
Indevus Pharmaceuticals Reports Positive Results of Phase II
Octreotide Implant Trial |
| November 28 |
Manhattan Pharmaceuticals Announces Positive Clinical Results for
Hedrin in Treatment of Head Lice |
| November 28 |
Promising Data ATIR Studies Presented by NIH Investigators |
| November 28 |
Transport's Phase 2 Data Show Single Treatment SoloVir ETS
Significantly Stops Progression of Cold Sore Episode |
| November 28 |
OXiGENE's Zybrestat Reported to Have Anti-Leukemic Effects in
Preclinical Studies Published in Blood |
| November 28 |
Immutep Announces Positive Interim Results From a Study of Immufact
IMP321 in Metastic Breast Cancer |
| November 28 |
Nymox Announces Positive Results in New 2 Year Blinded, Placebo
Controlled Study of NX-1207 for Benign Prostatic Hyperplasia |
| November 28 |
Anavex Advances Drug Candidate for Treatment of Alzheimer's Disease |
| November 28 |
Stallergenes: Oralair Grasses: Positive Results of VO52.06
Paediatric Study |
| November 28 |
St. Jude Researchers Identify Key Genetic Trigger of Acute Myeloid
Leukemia |
| November 28 |
Thomson Scientific Takes a Fresh Look at Multiauthor Papers |
| November 28 |
High Blood Pressure May Heighten Effects of Alzheimer's Disease |
| November 28 |
Sirtris and Harvard Unveil Promising, Novel SIRT1 Activators for
Treating Diseases of Aging; Therapeutic Type 2 Diabetes Data
Published in the Journal Nature |
| November 28 |
High-Trauma Fractures in Older Men and Women Linked to Osteoporosis |
| November 29 |
Micromet and MedImmune to Present New Clinical Data for Anti-CD19
BiTE Antibody at American Society of Hematology Annual Meeting
Showing Objective Clinical Responses in Relapsed Non-Hodgkin's
Lymphoma Patients |
| November 29 |
Pharmacyclics Announces Presentations on Its Novel BTK and HDAC
Inhibitors at the American Society of Hematology 49th Annual
Meeting |
| November 29 |
Osteoporosis: An Equal Opportunity Illness |
| November 29 |
CVBT to Present Disc Ischemia Preliminary Results at World Forum
for Spine Research Kyoto Meeting |
| November 29 |
First European Patient Treated in CABERNET Trial With Novel
Treatment for Wet AMD |
| November 29 |
Three Astex Drug Candidates to be Presented at the 2007 American
Society of Hematology Annual Meeting |
| November 29 |
Oncolytics Biotech Inc. to Present at Annual Vaccine Production
Conference |
| November 29 |
CytRx Phase IIa Open-Label Arimoclomol Data to Be Presented at the
18th International Symposium on ALS/MND |
| November 29 |
Thallion Demonstrates ECO-4601 Crosses the Blood Brain Barrier and
Selectively Targets Brain Tumours |
| November 29 |
Bavarian Nordic A/S Reports Positive Data from First EUA Enabling
Study with Imvamune Smallpox Vaccine |
| November 29 |
Aida Announces Completion of Anti-Cancer Drug Phase Two Testing |
| November 29 |
Forest Laboratories, Inc. Announces Positive Results of Lexapro
Phase III Study in Adolescents With Major Depression |
| November 29 |
Published Data Suggest That Erbitux Enables Complete Surgical
Resection of Colorectal Liver Metastases in Patients Previously
Refractory to Conventional Systemic Therapy |
| November 29 |
Gloucester Pharmaceuticals Announces Presentation of Romidepsin
Data at 2007 American Society of Hematology (ASH) Annual Meeting |
| November 29 |
Symptomatic Menopause Highlighted in Evidence-based Clinical
Overview |
| November 29 |
ImmunoGen, Inc. to Host Conference Call to Review Clinical Findings
Reported at ASH |
| November 30 |
Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy
CHR-2797 |
| November 30 |
Alpharma's Phase III Pivotal Clinical Placebo-Controlled Trial of
Its Abuse-Deterrent, Extended-Release Opioid Demonstrates
Significant Efficacy |
| November 30 |
Sunesis Pharmaceuticals to Present Data on Two Product Candidates
at the 49th Annual Meeting of the American Society of Hematology |
| November 30 |
Crucell Presents Indian Phase I Rabies Antibody Cocktail Study,
Positive Results Enable Prompt Progression Towards Phase II Studies |
| November 30 |
Forest Laboratories and Lundbeck announces positive results of
Lexapro phase III study in adolescents with major depression |
| November 30 |
Bavarian Nordic Reports Positive Data from First EUA Enabling Study
with IMVAMUNE Smallpox Vaccine Candidate |
| November 30 |
Biological Psychiatry Publishes Study Showing Vyvanse Demonstrated
Significant Efficacy for Treatment of ADHD for up to 12 Hours After
Administration |
| November 30 |
Bionovo Describes a New Class of Therapeutic Compounds |
| November 30 |
Biological Psychiatry Publishes Study Showing Vyvanse Demonstrated
Significant Efficacy for Treatment of ADHD for up to 12 Hours After
Administration |
| November 30 |
Avexa's ATC Demonstrates Activity Against Emerging Class Resistance |
